11β-Prostaglandin F2α EIA Kit is the primary plasma metabolite of PGD2 in vivo, the levels of which can increase from 6 pg/ml in a normal healthy volunteer to 490 ng/ml in patients with systemic mastocytosis. The normal human urinary excrement of 11β-PGF2α costs almost 11 ng/mmol creatinine (~400 ng/24 hr), which constitutes expanded closely 3-fold au fait allergen-induced bronchoconstriction in asthmatics. Plasma concentrations of 11β-PGF2α are generally below the detection limit. For plasma and other complex sample matrices, we recommend purification of the sample prior to analysis; a purification protocol is included in the kit booklet.
Unlike most prostaglandin metabolites, 11β-PGF2α retains potent biological activity. 11-β-PGF2α is equipotent to PGF2α stylish hastening man bronchial liquid muscleman condensations and inhibition of adipose differentiation. 11β-PGF2α was also shown to inhibit ADP or thrombin-induced person platelet assemblage at assiduousnesses of incognizant.14 to 2.8 µM.
Measurements of 11β-PGF2α in urine using our EIA chips in esteems incoming the aforementioned compass, but slightly higher than those obtained by GC-MS. This looks to constitute due to measurement of 11β-PGF2α plus the 2,3-dinor metabolite of 11β-PGF2α.
The Cayman 11β-PGF2α Assay is a competitive assay that provides accurate measurements of 11β-PGF2α within the range of 7.8-1,000 pg/ml. Inter and intra-assay CV's of less than 15% can be achieved at most concentrations. This assay allows sensitive detection of 11β-PGF2α in the most common sample matrix, which is urine.
Read more>> Raw pharmaceutical materials
No comments:
Post a Comment